Bayer: 5 key drugs to have combined peak sales of 5.5 bln eur

LEVERKUSEN, Germany Wed Nov 14, 2012 4:20am EST

LEVERKUSEN, Germany Nov 14 (Reuters) - Bayer said its five most promising new drugs have an annual peak sales potential of more than 5.5 billion euros ($7 billion).

The sales forecast comprises anti-clotting pill Xarelto, ophthalmic drug Eylea, also calle VEGF Trap-Eye, anti-cancer products Alpharadin and Stivarga, as well as lung treatment riociguat.

Last year, Bayer said four of the drugs, excluding riociguat, would have a peak sales potential of more than 5 billion euros.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.